logo
Plus   Neg
Share
Email

Stock Alert: Axsome Therapeutics Up 25% As Alzheimer's Drug Achieves Main Goal

Shares of Axsome Therapeutics, Inc. (AXSM) surged over 25% on Monday morning after the clinical-stage biopharmaceutical company's lead investigational drug for Alzheimer's disease agitation achieved positive results in a study.

AXSM is currently trading at $96.89, up $20.49 or 26.82%, on the Nasdaq.

Axsome Therapeutics announced that its investigational drug AXS-05 met the primary endpoint in the Phase 2/3 trial. The drug rapidly, substantially, and significantly improved agitation in patients with Alzheimer's disease as compared to placebo.

The study conducted on 366 Alzheimer's disease patients.

There are currently no FDA-approved treatments for Alzheimer's disease agitation. Alzheimer's disease is the most common form of dementia and is characterized by cognitive decline, and behavioral and psychological symptoms including agitation. Agitation is observed in up to 70% of patients with Alzheimer's disease.

AXS-05 has been granted FDA Fast Track designation for the treatment of Alzheimer's disease agitation.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Walt Disney World, the Orlando, Florida-based entertainment complex, is easing the health safety guidelines that were rolled out to prevent the spread of the ongoing COVID-19 pandemic. The complex is ending temperature checks in a phased manner following the advice of the Centers for Disease Control and Prevention (CDC) and local health officials. Frito-Lay North America, the convenient foods division of food and beverages giant PepsiCo, Inc., is recalling select Ruffles All Dressed Potato Chips citing the possible presence of undeclared milk ingredients, a known allergen, the U.S. Food and Drug Administration said. According to the agency, the recalled products may have distributed regionally to Walmart's Sam's Club Warehouses. Pfizer Inc. (PFE) and BioNTech SE (BNTX) announced Friday that they have initiated the Biologics License Application (BLA) process with the U.S. Food and Drug Administration (FDA) for approval of their mRNA vaccine to prevent COVID-19 in individuals 16 years of age and older. The companies initiated...
Follow RTT